Adage Capital Partners Gp, L.L.C. Amylyx Pharmaceuticals, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $59.7 Billion
- Q3 2025
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 6,816,828 shares of AMLX stock, worth $86.5 Million. This represents 0.16% of its overall portfolio holdings.
Number of Shares
6,816,828
Previous 8,800,000
22.54%
Holding current value
$86.5 Million
Previous $56.4 Million
64.23%
% of portfolio
0.16%
Previous 0.1%
Shares
10 transactions
Others Institutions Holding AMLX
# of Institutions
180Shares Held
94.1MCall Options Held
421KPut Options Held
174K-
Perceptive Advisors LLC New York, NY8.95MShares$114 Million0.27% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA6.24MShares$79.2 Million9.51% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.27MShares$66.9 Million0.0% of portfolio
-
Saturn V Capital Management LLC Austin, TX4.6MShares$58.4 Million13.72% of portfolio
-
Commodore Capital LP New York, NY4.08MShares$51.7 Million3.54% of portfolio
About Amylyx Pharmaceuticals, Inc.
- Ticker AMLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,533,200
- Market Cap $743M
- Description
- Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...